NVST - Envista expands dental portfolio with acquisition of Osteogenics

Envista (NYSE:NVST) on Tuesday said it would acquire dental bone grafting products maker Osteogenics. Envista, which is comprised of more than 30 dental brands, offers products and services such as dental implants and treatment options, orthodontics, and digital imaging technologies. Lubbock, Texas-based Osteogenics offers a line of bone grafting products, primarily sold under the Cytoplast brand name. The terms of the deal were not disclosed. The deal is subject to customary regulatory approvals and is expected to close in Q3. Envista also said the deal is not subject to a financing condition or shareholder vote. NVST stock earlier closed +2.7% at $42.92.

For further details see:

Envista expands dental portfolio with acquisition of Osteogenics